Sector portfolio · Private equity · United Kingdom

Janus Henderson Investors' Pharma portfolio

Janus Henderson Investors has backed 35 Pharma startups in rounds we track, $6.2B between them, shown by the stage each has reached. The best-funded is Dianthus Therapeutics.

35startups backed
4stages
$6.2Braised between them
Stage not reportedbiggest stage

Janus Henderson Investors's whole portfolioJanus Henderson Investors's profile

Stage not reported

17

Series B

8

Series C and later

7

Series A

3

Segment by segment

Stage not reported

17 startups · $2.9B raised

  1. Dianthus TherapeuticsDianthus Therapeutics is a biotech company developing new treatments for serious autoimmune diseases using a more targeted approach.United States$719M
  2. VaxcyteVaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.United States$633M
  3. Maze TherapeuticsMaze Therapeutics is an operator of a biotechnology firm used to focus on translating genetic insights into new medicines.United States$300M
  4. Edgewise TherapeuticsEdgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.United States$200M
  5. Jade BiosciencesJade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications.United States$195M
  6. Day One BiopharmaceuticalsDay One Biopharmaceuticals develops targeted therapies to treat people with life-threatening diseases.United States$175M
  7. Bicara TherapeuticsBicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.United States$150M
  8. MonoparMonopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds.United States$147M

Series B

8 startups · $1.1B raised

  1. Draig TherapeuticsDraig Therapeutics is a clinical-stage biotechnology company based in Cardiff, Wales, focused on developing innovative neuropsychiUnited Kingdom$216M
  2. MetseraMetsera operates as a clinical-stage biopharmaceutical company.United States$215M
  3. OcugenOcugen is a biotechnology company that develops novel gene and cell therapies to improve health and patient outcomes.United States$151M
  4. Diagonal TherapeuticsDiagonal Therapeutics is developing a new class of clustering antibody medicines designed to address the root causes of severe genUnited States$125M
  5. Claris BiotherapeuticsClaris Biotherapeutics is a late-clinical stage biotechnology company based in Jersey City, New Jersey.United States$124M
  6. CurevoCurevo is a clinical-stage biotech firm that focuses on producing vaccines.United States$110M
  7. Rain OncologyRain Oncology is a clinical-stage company focusing on research and development of innovative therapies for cancer patients.-$63M
  8. AttralusAttralus is a clinical-stage biopharmaceutical company focused on developing innovative medicines and diagnostics for systemic amyloidosis.United States$56M

Series C and later

7 startups · $1.4B raised

  1. OMass TherapeuticsOMass Therapeutics is a biotechnology company located in Oxford, UK, focused on discovering and developing novel small molecule meUnited Kingdom$442M
  2. Parabilis MedicinesParabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specializes in creating medicines.United States$380M
  3. Ovid TherapeuticsOvid Therapeutic's purpose is to solve intractable medical problems.United States$166M
  4. Artios PharmaArtios Pharma is a independent DNA Damage Response company with a strong pipeline of novel cancer therapies.United Kingdom$148M
  5. Angitia BiopharmaceuticalsAngitia Biopharmaceuticals is a clinical-stage biotechnology company founded in 2018, dedicated to developing innovative therapiesUnited States$130M
  6. Cyteir TherapeuticsCyteir is developing the next generation of synthetic lethal therapies to treat cancer.United States$126M
  7. 35Pharma35Pharma is a biopharmaceutical company that designs and develops innovative biologics for diseases of high unmet medical need.Canada$53M

Series A

3 startups · $825M raised

  1. Korsana BiosciencesKorsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases including Alzheimer’s.United States$530M
  2. Compass TherapeuticsCompass Therapeutics is a biopharmaceutical company that focuses on drugging the immune system to treat human diseases.United States$257M
  3. Caldera TherapeuticsCaldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).United States$38M

How this map is made. Every startup here works in Pharma and has raised money in a round we track that names Janus Henderson Investors as an investor. Each sits under the stage of its latest round. Rebuilt nightly; updated 15 November 2026.

More portfolio maps

All portfolios
Sector portfolioJanus Henderson Investors' Biotech portfolio89 startups · $21BPortfolio mapJanus Henderson Investors portfolio map128 startups · $28BInvestments abroadJanus Henderson Investors' investments in the United States111 startups · $23BCo-investorsWho invests with Janus Henderson Investors80 co-investorsSector portfolioDST Global's AI portfolio30 startups · $203BSector portfolioDST Global's Fintech portfolio23 startups · $18B

Raising from investors like Janus Henderson Investors?

Find the investors who back startups like yours, with their cheques, rounds and partners, in the app with filters, lists and exports.

Find investorsMarket maps